EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieKlinische Studie (Phase I)Open Access · CC BY 4.0

Phase I/II clinical trial of brentuximab vedotin for pretreated Japanese patients with CD30 ‐positive cutaneous T‐cell lymphoma

Yoji Hirai iD, Jun Sakurai, Shiho Yoshida, Takashi Kikuchi, Toshiharu Mitsuhashi, Tomoko Miyake iD, Taku Fujimura iD, Riichiro Abe iD, Hiroki Fujikawa, Hikari Boki, Hiraku Suga, Sayaka Shibata iD und 5 weitere

The Journal of Dermatology · 2024

DOI: 10.1111/1346-8138.17324 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift The Journal of Dermatology, 2024. Verfasst von Yoji Hirai und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Okayama, Japan. Hauptthemen laut MEDLINE: Brentuximab Vedotin, Ki-1 Antigen, Skin Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceutical Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Brentuximab vedotin (BV), a conjugate of anti‐CD30 antibody and monomethyl auristatin E, has emerged as a promising treatment option for refractory CD30+ mycosis fungoides (MF) and primary cutaneous anaplastic large‐cell lymphoma (pcALCL). BV has been shown to be safe and effective in treating Hodgkin's lymphoma and peripheral T‐cell lymphoma. This multicenter, prospective, single‐arm phase I/II study evaluated the efficacy of BV in Japanese patients with CD30+ cutaneous lymphomas, namely CD30+ cutaneous T‐cell lymphoma. Participants were divided into two groups: those with CD30+ MF or pcALCL (cohort 1, n = 13) and those with CD30+ lymphoproliferative disorders other than those in cohort 1 (cohort 2, n = 3). The studied population included the full analysis set (FAS), modified FAS (mFAS), and safety analysis set (SAF). These sets were identified in cohorts 1 and 1 + 2 and labeled FAS1 and FAS2, mFAS1 and mFAS2, and SAF1 and SAF2, respectively. Each treatment cycle lasted 3 weeks, and BV was continued for up to 16 cycles after the third cycle based on treatment response. The primary endpoint was the 4‐month objective response rate (ORR4) determined by the Independent Review Forum (IRF). ORR4 was 69.2% for FAS1 and 62.5% for FAS2 ( P < 0.0001). Secondary endpoints of ORR, assessed using the global response score (53.8% in FAS1) and modified severity‐weighted assessment tool (62.5% in FAS1), using the IRF, provided results comparable to the primary findings. The incidence of ≥grade 3 adverse events (≥15%) in SAF1 was peripheral neuropathy in three patients (23%) and fever and eosinophilia in two patients (15%). In conclusion, BV showed favorable efficacy, tolerability, and safety profile in Japanese patients with relapsed or refractory CD30+ primary cutaneous T‐cell lymphoma. The trial was registered with University Hospital Medical Information Network Clinical Trials Registry, Japan (protocol ID: UMIN000034205).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brentuximab VedotinKi-1 AntigenSkin NeoplasmsHumansMaleMiddle AgedFemaleAgedProspective StudiesJapanAdultAged, 80 and overMycosis FungoidesLymphoma, T-Cell, CutaneousAntineoplastic Agents, ImmunologicalImmunoconjugatesTreatment OutcomeEast Asian People

Stichwörter der Autor:innen

anaplastic large‐cell lymphomabrentuximab vedotincutaneous T‐cell lymphomamycosis fungoidesperipheral T‐cell lymphoma

Substanzen

Brentuximab VedotinKi-1 AntigenAntineoplastic Agents, ImmunologicalImmunoconjugates

Autor:innen und Institutionen

  • Department of Dermatology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
  • Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan.
  • Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Department of Dermatology, Niigata University, Niigata, Japan.
  • Department of Dermatology, Tokyo University, Tokyo, Japan.
  • Department of Dermatology, Hamamatsu University School of Medicine, Hamamatsu, Japan.

ORCID-Profile: Yoji Hirai, Tomoko Miyake, Taku Fujimura, Riichiro Abe, Sayaka Shibata, Tomomitsu Miyagaki, Takatoshi Shimauchi, Yoshio Kawakami, Shin Morizane

Förderung

  • Takeda Pharmaceutical Company

Zitieren

APA

Hirai, Y., Sakurai, J., Yoshida, S., Kikuchi, T., Mitsuhashi, T., Miyake, T., Fujimura, T., Abe, R., Fujikawa, H., Boki, H., Suga, H., Shibata, S., Miyagaki, T., Shimauchi, T., Kiyohara, E., Kawakami, Y., & Morizane, S. (2024). Phase I/II clinical trial of brentuximab vedotin for pretreated Japanese patients with CD30 ‐positive cutaneous T‐cell lymphoma. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17324

Vancouver

Hirai Y, Sakurai J, Yoshida S, Kikuchi T, Mitsuhashi T, Miyake T, et al. Phase I/II clinical trial of brentuximab vedotin for pretreated Japanese patients with CD30 ‐positive cutaneous T‐cell lymphoma. The Journal of Dermatology. 2024. doi:10.1111/1346-8138.17324

BibTeX
@article{Hirai2024,
  author = {Hirai, Yoji and Sakurai, Jun and Yoshida, Shiho and Kikuchi, Takashi and Mitsuhashi, Toshiharu and Miyake, Tomoko and Fujimura, Taku and Abe, Riichiro and Fujikawa, Hiroki and Boki, Hikari and Suga, Hiraku and Shibata, Sayaka and Miyagaki, Tomomitsu and Shimauchi, Takatoshi and Kiyohara, Eiji and Kawakami, Yoshio and Morizane, Shin},
  title = {Phase I/II clinical trial of brentuximab vedotin for pretreated Japanese patients with CD30 ‐positive cutaneous T‐cell lymphoma},
  journal = {The Journal of Dermatology},
  year = {2024},
  doi = {10.1111/1346-8138.17324}
}
Kostenlos starten →